166 related articles for article (PubMed ID: 18163511)
1. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees.
Schuelert N; McDougall JJ
Arthritis Rheum; 2008 Jan; 58(1):145-53. PubMed ID: 18163511
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain.
Schuelert N; Zhang C; Mogg AJ; Broad LM; Hepburn DL; Nisenbaum ES; Johnson MP; McDougall JJ
Osteoarthritis Cartilage; 2010 Nov; 18(11):1536-43. PubMed ID: 20863899
[TBL] [Abstract][Full Text] [Related]
3. The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints.
Baker CL; McDougall JJ
Br J Pharmacol; 2004 Aug; 142(8):1361-7. PubMed ID: 15277316
[TBL] [Abstract][Full Text] [Related]
4. Peripheral cannabinoid CB1 receptors inhibit evoked responses of nociceptive neurones in vivo.
Kelly S; Donaldson LF
Eur J Pharmacol; 2008 May; 586(1-3):160-3. PubMed ID: 18410918
[TBL] [Abstract][Full Text] [Related]
5. Opposing roles for cannabinoid receptor type-1 (CB₁) and transient receptor potential vanilloid type-1 channel (TRPV1) on the modulation of panic-like responses in rats.
Casarotto PC; Terzian AL; Aguiar DC; Zangrossi H; Guimarães FS; Wotjak CT; Moreira FA
Neuropsychopharmacology; 2012 Jan; 37(2):478-86. PubMed ID: 21937980
[TBL] [Abstract][Full Text] [Related]
6. Proteinase-activated receptor-4 (PAR4) activation leads to sensitization of rat joint primary afferents via a bradykinin B2 receptor-dependent mechanism.
Russell FA; Veldhoen VE; Tchitchkan D; McDougall JJ
J Neurophysiol; 2010 Jan; 103(1):155-63. PubMed ID: 19889854
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiological evidence that the vasoactive intestinal peptide receptor antagonist VIP6-28 reduces nociception in an animal model of osteoarthritis.
Schuelert N; McDougall JJ
Osteoarthritis Cartilage; 2006 Nov; 14(11):1155-62. PubMed ID: 16740398
[TBL] [Abstract][Full Text] [Related]
8. Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis.
Schuelert N; Johnson MP; Oskins JL; Jassal K; Chambers MG; McDougall JJ
Pain; 2011 May; 152(5):975-981. PubMed ID: 21185649
[TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid and endovanilloid systems interact in the rat prelimbic medial prefrontal cortex to control anxiety-like behavior.
Fogaça MV; Aguiar DC; Moreira FA; Guimarães FS
Neuropharmacology; 2012 Aug; 63(2):202-10. PubMed ID: 22691536
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation.
Potenzieri C; Brink TS; Pacharinsak C; Simone DA
J Neurophysiol; 2008 Nov; 100(5):2794-806. PubMed ID: 18784270
[TBL] [Abstract][Full Text] [Related]
11. AM404 decreases Fos-immunoreactivity in the spinal cord in a model of inflammatory pain.
Borsani E; Labanca M; Bianchi R; Rodella LF
Brain Res; 2007 Jun; 1152():87-94. PubMed ID: 17459353
[TBL] [Abstract][Full Text] [Related]
12. Grading of monosodium iodoacetate-induced osteoarthritis reveals a concentration-dependent sensitization of nociceptors in the knee joint of the rat.
Schuelert N; McDougall JJ
Neurosci Lett; 2009 Nov; 465(2):184-8. PubMed ID: 19716399
[TBL] [Abstract][Full Text] [Related]
13. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels.
Micale V; Cristino L; Tamburella A; Petrosino S; Leggio GM; Drago F; Di Marzo V
Neuropsychopharmacology; 2009 Feb; 34(3):593-606. PubMed ID: 18580871
[TBL] [Abstract][Full Text] [Related]
14. Chronic arthritis down-regulates peripheral mu-opioid receptor expression with concomitant loss of endomorphin 1 antinociception.
Li Z; Proud D; Zhang C; Wiehler S; McDougall JJ
Arthritis Rheum; 2005 Oct; 52(10):3210-9. PubMed ID: 16200625
[TBL] [Abstract][Full Text] [Related]
15. Paracetamol-induced hypothermia is independent of cannabinoids and transient receptor potential vanilloid-1 and is not mediated by AM404.
Ayoub SS; Pryce G; Seed MP; Bolton C; Flower RJ; Baker D
Drug Metab Dispos; 2011 Sep; 39(9):1689-95. PubMed ID: 21628499
[TBL] [Abstract][Full Text] [Related]
16. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats.
Bermúdez-Siva FJ; Serrano A; Diaz-Molina FJ; Sánchez Vera I; Juan-Pico P; Nadal A; Fuentes E; Rodríguez de Fonseca F
Eur J Pharmacol; 2006 Feb; 531(1-3):282-4. PubMed ID: 16423347
[TBL] [Abstract][Full Text] [Related]
17. Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo.
Kelly S; Chapman V
J Neurophysiol; 2001 Dec; 86(6):3061-4. PubMed ID: 11731561
[TBL] [Abstract][Full Text] [Related]
18. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis.
Gutierrez T; Farthing JN; Zvonok AM; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Jan; 150(2):153-63. PubMed ID: 17160008
[TBL] [Abstract][Full Text] [Related]
19. Anticonvulsant effects of N-arachidonoyl-serotonin, a dual fatty acid amide hydrolase enzyme and transient receptor potential vanilloid type-1 (TRPV1) channel blocker, on experimental seizures: the roles of cannabinoid CB1 receptors and TRPV1 channels.
Vilela LR; Medeiros DC; de Oliveira AC; Moraes MF; Moreira FA
Basic Clin Pharmacol Toxicol; 2014 Oct; 115(4):330-4. PubMed ID: 24674273
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity.
Walczak JS; Price TJ; Cervero F
Neuroscience; 2009 Mar; 159(3):1154-63. PubMed ID: 19356696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
